Company
Vectura Group plc
Headquarters: Chippenham, United Kingdom
Founded: 1997
Employees: 450
Market Cap
£1.00 Billion
GBP as of Oct. 1, 2021
US$1.36 Billion
Vectura Group plc Categories
United Kingdom Healthcare Drug Manufacturers—GeneralUnited Kingdom Healthcare United Kingdom Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
| AbbVie | $295.34 B |
| AstraZeneca | $236.45 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Vectura Group plc has the following listings and related stock indices.
Stock: LSE: VEC wb_incandescent
Stock: FSX: V4TA wb_incandescent
Stock: OTC: VEGPF wb_incandescent
Key People
Bruno Angelici, Chairman Will Downie, (CEO)
Financials
Revenue: £190.6 million (2020)
Operating income: £132.8 million (2020)
Net income: £122.4 million (2020)